Comparative Pharmacology
Head-to-head clinical analysis: CYTOXAN versus VALCHLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOXAN versus VALCHLOR.
CYTOXAN vs VALCHLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell cycle nonspecific cytotoxicity. It requires hepatic activation by cytochrome P450 enzymes to form active metabolites, primarily phosphoramide mustard.
Valchlor (mechlorethamine) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, leading to inhibition of DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
500-1500 mg/m² IV every 2-4 weeks or 1-5 mg/kg/day PO for 10-14 days.
Topical: Apply 0.016% mechlorethamine gel to affected areas once daily.
None Documented
None Documented
Terminal elimination half-life of cyclophosphamide is 3-12 hours (range 2-19 h) in adults; the half-life of active metabolites (e.g., 4-hydroxycyclophosphamide) is approximately 8-10 hours. Half-life is prolonged in hepatic impairment (up to 20 h) and reduced in dose adjustments.
The terminal elimination half-life is approximately 24 hours after topical application, supporting daily dosing. Systemic half-life may be prolonged in patients with hepatic impairment.
Renal elimination of unchanged cyclophosphamide (5-30%) and metabolites (primarily 4-ketocyclophosphamide and carboxyphosphamide) accounts for approximately 80% of total clearance; fecal excretion is minimal (<5%).
Following topical application, VALCHLOR (mechlorethamine) is systemically absorbed; approximately <10% is excreted unchanged in urine. The majority of the dose is eliminated via metabolism and biliary/fecal routes, with ~50% of a systemic dose recovered in feces as metabolites.
Category C
Category C
Alkylating Agent
Alkylating Agent